Anapa

Researchers are evaluating the effectiveness and tolerability of Lusefi4, a medication prescribed to adults with type 2 diabetes, in real-world clinical practice. This observational study focuses on how well Lusefi4 controls blood sugar and its impact on metabolic and hemodynamic health factors over approximately six months. Participants will take 2.5 mg of Lusefi4 once daily, with the possibility of increasing to 5 mg daily if the initial response is insufficient, as determined by their usual doctor. The study follows patients who have already begun treatment recently and observes them under routine care conditions without additional interventions. During the six-month observation period, researchers will monitor blood sugar control by measuring glycated hemoglobin HbA1c, plasma glucose, body weight, blood pressure, kidney function, lipid levels, and uric acid. Data will be collected from routine clinical visits, focusing on these health parameters to understand the medications effects and tolerability in everyday use.